Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery
mmAOM treatment yields the highest %TBWL, especially within the first 51 weeks of preoperative preparation, demonstrating superior efficacy over Mono-GLP-1 and NP-MSWL in patients with BMI ≥ 70 kg/m². These findings suggest that incorporating mmAOM in preoperative protocols could optimize weight loss and improve surgical outcomes for high BMI patients.
Authors
- Michael W. Cook (ORCID: https://orcid.org/0000-0001-6719-7379)
- Vance L. Albaugh (ORCID: https://orcid.org/0000-0002-5267-8951)
- Brian P. Saunders (ORCID: https://orcid.org/0000-0002-4190-7448)
- Denise Danos (ORCID: https://orcid.org/0000-0001-6256-0861)
- Michael Kachmar (ORCID: https://orcid.org/0000-0001-8959-6565)
- Jean Wysler Domerçant (ORCID: https://orcid.org/0000-0001-7995-4111)
- Philip R. Schauer (ORCID: https://orcid.org/0000-0002-4029-7537)
- Kyle B LaPenna
- Iryna Popiv
- Florina Corpodean
Institutions
- Pennington Biomedical Research Center (US)
- University Medical Center New Orleans (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Franciscan Missionaries of Our Lady University (US)
Publication Details
- Journal
- International Journal of Obesity
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1038/s41366-025-01798-2
- Citations
- 3
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 6.02